NYMC Faculty Publications

Unrelated Donor Allogeneic Transplantation After Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study From the Center for International Blood and Marrow Transplantation Research

Author Type(s)

Faculty

DOI

10.1016/j.bbmt.2013.04.022

Journal Title

Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation

First Page

1102

Last Page

1108

Document Type

Article

Publication Date

7-1-2013

Abstract

The survival of patients with relapsed acute myelogenous leukemia (AML) after autologous hematopoietic stem cell transplantation (auto-HCT) is very poor. We studied the outcomes of 302 patients who underwent secondary allogeneic hematopoietic cell transplantation (allo-HCT) from an unrelated donor (URD) using either myeloablative (n = 242) or reduced-intensity conditioning (RIC; n = 60) regimens reported to the Center for International Blood and Marrow Transplantation Research. After a median follow-up of 58 months (range, 2 to 160 months), the probability of treatment-related mortality was 44% (95% confidence interval [CI], 38%-50%) at 1-year. The 5-year incidence of relapse was 32% (95% CI, 27%-38%), and that of overall survival was 22% (95% CI, 18%-27%). Multivariate analysis revealed a significantly better overal survival with RIC regimens (hazard ratio [HR], 0.51; 95% CI, 0.35-0.75; P18 months) from auto-HCT to URD allo-HCT was associated with significantly lower riak of relapse (HR, 0.19; 95% CI, 0.09-0.38; P

Link to Full Text

Share

COinS